Latest Breaking News On - Zevra therapeutics inc - Page 11 : comparemela.com

Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference - Zevra Therapeutics (NASDAQ:ZVRA)

CELEBRATION, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will present at the upcoming Oppenheimer

David schullNichol ochsnerIgnacio guerrero rosHealthcare life sciences conferenceZevra therapeutics incCompany expanded access programExchange commissionAnnual healthcare life sciences conferenceInvestor relationsZevra therapeuticsExpanded access programNote concerning forward looking statementsPrivate securities litigation reform actAnnual reportQuarterly reportWhile zevra

TScan Therapeutics Appoints Seasoned Industry Executive Jason A Amello as Chief Financial Officer

29.01.2024 - WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) - TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of . Seite 1

Boston collegeBoard of directors acer therapeutics incZevra therapeutics incStrategic financial servicesAkebia therapeutics incZiopharm oncology incGenzyme corporationAlaunos therapeutics incCandel therapeutics incCandel therapeuticsChief financial officerAkebia therapeuticsZiopharm oncologyAlaunos therapeuticsSenior vice presidentChief accounting

LadRx Issues 2024 Update to Shareholders

FDA Acceptance of Arimoclomol Triggers $1 Million Payment .

South africaStephen snowdyImmunitybio incZevra therapeutics incGood laboratory practicesLadrx corporationDrug administrationZevra incLadrx shareholdersZevra therapeuticsNew drug applicationPrescription drug user fee actGood manufacturing practicesInvestigational new drug

Zevra Therapeutics Says FDA Accepts Resubmission Of Arimoclomol NDA In Niemann-Pick Disease Type C

Rare disease therapeutics company Zevra Therapeutics, Inc. (ZVRA) announced Monday that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the New Drug Application (NDA) for arimoclomol as an orally-delivered, first-in-class treatment for Niemann-Pick disease type C.

Drug administrationZevra therapeutics incZevra therapeuticsNew drug applicationPrescription drug user fee actNew drug applicationUs food and drug administrationNiemann pick disease type cZevra therapeuticsAre disease therapeutics company zevra

Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David schullNichol ochsnerNeilf mcfarlaneIgnacio guerrero rosZevra therapeutics incEuropean medicines agencyCompany expanded access programExchange commissionDrug administrationNew drug applicationPrescription drug user fee actChief executive officerOrphan drugFast trackBreakthrough therapyRare pediatric disease